Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study

Onglets principaux

Buysschaert, Martin [UCL] Baeck, Marie [UCL] Preumont, Vanessa [UCL] Marot, Liliane [UCL] Hendrickx, Emilie [UCL] Van Belle, Astrid [UCL] Dumoutier, Laure [UCL]

BACKGROUND: A few case reports suggest that incretin-based therapies could improve psoriasis in patients with type 2 diabetes, the mechanism(s) of which remain unclear. OBJECTIVES: To determine the effects after 16-20 weeks of treatment with a glucagon-like peptide (GLP)-1 analogue on clinical severity and histopathological aspects of psoriasis in patients with type 2 diabetes, and to examine the presence of γδ T cells and the expression of interleukin (IL)-17 in psoriasis before and after treatment. METHODS: Seven patients with type 2 diabetes and psoriasis were followed. Psoriasis Area and Severity Index (PASI) was measured at baseline (T0) and after 7 ± 1 (T1) and 18 ± 2 (T2) weeks' treatment with exenatide/liraglutide. The histopathological pattern of psoriasis, and flow cytometry and immunological data (γδ T-cell percentage and IL-17 expression) were obtained from psoriatic and control sites. RESULTS: The mean PASI decreased from 12·0 ± 5·9 to 9·2 ± 6·4 (P = 0·04). Histological analysis showed a reduction in epidermal thickness after treatment. The dermal γδ T-cell percentage was higher in psoriatic lesions than in control specimens (P = 0·03), as was IL-17 expression (P = 0·018). A reduction of γδ T cells from 6·7 ± 4·5% to 2·7 ± 3·8% (P = 0·05) was demonstrated in the six patients with improved/unchanged PASI. A correlation between PASI and γδ T-cell percentage evolution during therapy (T2-T0) was noted (r = 0·894, P = 0·007). IL-17 was reduced in the four patients with the highest PASI reductions. CONCLUSIONS: The administration of a GLP-1 analogue improved clinical psoriasis severity in patients with type 2 diabetes. This favourable outcome was associated with a decrease of dermal γδ T-cell number and IL-17 expression. Further studies are needed to establish long-term efficacy in (diabetic) patients with psoriasis.

Type de document Article de périodique (Journal article) – Article de recherche
Type d'accès Accès restreint
Année de publication 2014
Langue Anglais
Information sur le périodique "British Journal of Dermatology" - Vol. 171, no. 1, p. 155-161 (2014)
Peer reviewed oui
Editeur Blackwell Scientific Publications ((United Kingdom) Oxford)
issn 0007-0963
e-issn 1365-2133
Statut de la publication Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - SSS/IREC/LUNS - Pôle pneumologie, ORL (airways) et dermatologie (skin)
UCL - (SLuc) Service d'endocrinologie et de nutrition
UCL - (SLuc) Service de dermatologie
UCL - (SLuc) Service d'anatomie pathologique
Liens
  1. Schön Michael P., Boehncke W.-Henning, Psoriasis, 10.1056/nejmra041320
  2. Nestle Frank O., Kaplan Daniel H., Barker Jonathan, Psoriasis, 10.1056/nejmra0804595
  3. Waite Janelle C., Skokos Dimitris, Th17 Response and Inflammatory Autoimmune Diseases, 10.1155/2012/819467
  4. Kanai Y, Satoh T, Igawa K, Yokozeki H, Impaired Expression of Tim-3 on Th17 and Th1 Cells in Psoriasis, 10.2340/00015555-1285
  5. Cai Yihua, Fleming Chris, Yan Jun, Dermal γδ T cells — A new player in the pathogenesis of psoriasis, 10.1016/j.intimp.2013.02.018
  6. Sommer Dorothea M., Jenisch Stefan, Suchan Michael, Christophers Enno, Weichenthal Michael, Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis, 10.1007/s00403-006-0703-z
  7. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., Giannetti A., Girolomoni G., Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study, 10.1111/j.1365-2133.2007.07986.x
  8. Armstrong A W, Harskamp C T, Armstrong E J, The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies, 10.1038/nutd.2012.26
  9. Gottlieb Alice B., Dann Frank, Comorbidities in Patients with Psoriasis, 10.1016/j.amjmed.2009.06.021
  10. Li Wenqing, Han Jiali, Hu Frank B., Curhan Gary C., Qureshi Abrar A., Psoriasis and Risk of Type 2 Diabetes among Women and Men in the United States: A Population-Based Cohort Study, 10.1038/jid.2011.319
  11. Azfar Rahat S., Seminara Nicole M., Shin Daniel B., Troxel Andrea B., Margolis David J., Gelfand Joel M., Increased Risk of Diabetes Mellitus and Likelihood of Receiving Diabetes Mellitus Treatment in Patients With Psoriasis, 10.1001/archdermatol.2012.1401
  12. Xu, Eur J Dermatol, 22, 396 (2012)
  13. Buysschaert M., Preumont V., Oriot P.R., Paris I., Ponchon M., Scarnière D., Selvais P., One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice, 10.1016/j.diabet.2010.03.009
  14. Preumont V., Hermans M.-P., Brichard S., Buysschaert M., Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity, 10.1016/j.diabet.2010.02.001
  15. Drucker Daniel J., The biology of incretin hormones, 10.1016/j.cmet.2006.01.004
  16. Ahern T., Tobin A.-M., Corrigan M., Hogan A., Sweeney C., Kirby B., O’Shea D., Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study : GLP-1 analogue therapy for psoriasis, 10.1111/j.1468-3083.2012.04609.x
  17. Buysschaert M., Tennstedt D., Preumont V., Improvement of psoriasis during exenatide treatment in a patient with diabetes, 10.1016/j.diabet.2011.11.004
  18. Faurschou A., Knop F. K., Thyssen J. P., Zachariae C., Skov L., Vilsbøll T., Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide, 10.1007/s00592-011-0359-9
  19. Hogan A. E., Tobin A. M., Ahern T., Corrigan M. A., Gaoatswe G., Jackson R., O’Reilly V., Lynch L., Doherty D. G., Moynagh P. N., Kirby B., O’Connell J., O’Shea D., Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis, 10.1007/s00125-011-2232-3
  20. Puzenat E, Bronsard V, Prey S, Gourraud P-A, Aractingi S, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Paul C, Richard-Lallemand M-A, Ortonne J-P, Aubin F, What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature, 10.1111/j.1468-3083.2009.03562.x
  21. Hanas R., John G., , 2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1c Measurement, 10.1373/clinchem.2010.150540
  22. Baeck Marie, Soria Angèle, Marot Liliane, Theate Ivan, Hendrickx Emilie, Van Belle Astrid, Goossens An, Tennstedt Dominique, Dachelet Claire, Jaeger Johnathan, Pilette Charles, Renauld Jean-Christophe, Van Baren Nicolas, Rozières Aurore, Nicolas Jean-Fançois, Dumoutier Laure, Characterization of the T cell response in allergic contact dermatitis caused by corticosteroids, 10.1111/cod.12040
  23. Chaudhuri Ajay, Ghanim Husam, Vora Mehul, Sia Chang Ling, Korzeniewski Kelly, Dhindsa Sandeep, Makdissi Antoine, Dandona Paresh, Exenatide Exerts a Potent Antiinflammatory Effect, 10.1210/jc.2011-1508
  24. Drucker D. J., Rosen C. F., Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology, 10.1007/s00125-011-2297-z
  25. Laggner U., Di Meglio P., Perera G. K., Hundhausen C., Lacy K. E., Ali N., Smith C. H., Hayday A. C., Nickoloff B. J., Nestle F. O., Identification of a Novel Proinflammatory Human Skin-Homing V 9V 2 T Cell Subset with a Potential Role in Psoriasis, 10.4049/jimmunol.1100804
  26. Becher Burkhard, Pantelyushin Stanislav, Hiding under the skin: Interleukin-17–producing γδ T cells go under the skin?, 10.1038/nm.3016
  27. Faurschou Annesofie, Zachariae Claus, Skov Lone, Vilsbøll Tina, Knop Filip K., Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?, 10.1016/j.mehy.2011.09.011
  28. Hossler Eric W., Maroon Michele S., Mowad Chris M., Gastric bypass surgery improves psoriasis, 10.1016/j.jaad.2010.01.001
  29. Hossler E.W., Wood G.C., Still C.D., Mowad C.M., Maroon M.S., The effect of weight loss surgery on the severity of psoriasis : Correspondence, 10.1111/j.1365-2133.2012.11211.x
  30. Laferrère B., Effect of gastric bypass surgery on the incretins, 10.1016/s1262-3636(09)73458-5
  31. Makdissi Antoine, Ghanim Husam, Vora Mehul, Green Kelly, Abuaysheh Sanaa, Chaudhuri Ajay, Dhindsa Sandeep, Dandona Paresh, Sitagliptin Exerts an Antinflammatory Action, 10.1210/jc.2012-1544
  32. Nishioka Tatsuya, Shinohara Masayuki, Tanimoto Noriyasu, Kumagai Chizuru, Hashimoto Kozo, Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis, 10.1159/000333358
Référence bibliographique Buysschaert, Martin ; Baeck, Marie ; Preumont, Vanessa ; Marot, Liliane ; Hendrickx, Emilie ; et. al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. In: British Journal of Dermatology, Vol. 171, no. 1, p. 155-161 (2014)
Permalien http://hdl.handle.net/2078.1/157540